Search

Your search keyword '"Barone, Stefania"' showing total 3 results
Start Over Author "Barone, Stefania" Database Supplemental Index
3 results on '"Barone, Stefania"'

1. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.

Author

Barone, Stefania, Scannapieco, Sara, Torti, Carlo, Filippelli, Enrica, Pisani, Vincenzo, Granata, Alfredo, Console, Domenico, Demonte, Giulio, Tallarico, Tiziana, Polidoro, Serena, Quattrone, Aldo, and Valentino, Paola

Abstract

The anti-CD52 monoclonal antibody alemtuzumab is a highly active treatment for multiple sclerosis (MS) causing rapid depletion of B and T lymphocytes with nadir one month after last infusion. Opportunistic Cytomegalovirus (CMV) infections have been reported in MS patients treated with this drug. We report one patient who developed a CMV reactivation with hepatic involvement three weeks after the first cycle of alemtuzumab. This patient, promptly diagnosed and treated, achieved a complete recovery with valganciclovir. The possibility of this treatable opportunistic infection should be considered by neurologists in febrile patients with hepatic markers alteration after treatment with alemtuzumab. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

2. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment

Author

Barone, Stefania, Scannapieco, Sara, Torti, Carlo, Filippelli, Enrica, Pisani, Vincenzo, Granata, Alfredo, Console, Domenico, Demonte, Giulio, Tallarico, Tiziana, Polidoro, Serena, Quattrone, Aldo, and Valentino, Paola

Abstract

The anti-CD52 monoclonal antibody alemtuzumab is a highly active treatment for multiple sclerosis (MS) causing rapid depletion of B and T lymphocytes with nadir one month after last infusion. Opportunistic Cytomegalovirus (CMV) infections have been reported in MS patients treated with this drug.

Published
2018
Full Text
View/download PDF

3. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

Author

Maniscalco, Giorgia T., Saccà, Francesco, Lanzillo, Roberta, Annovazzi, Pietro, Baroncini, Damiano, Binello, Eleonora, Repice, Annamaria, Perini, Paola, Clerico, Marinella, Mataluni, Giorgia, Bonavita, Simona, La Gioia, Sara, Gutierrez, Lorena Pareja, Laroni, Alice, Frau, Jessica, Cocco, Eleonora, Torri Clerici, Valentina, Zarbo, Ignazio Roberto, Sartori, Arianna, Signoriello, Elisabetta, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Cerqua, Raffaella, Pontecorvo, Simona, Di Sapio, Alessia, Grasso, Roberta, Barone, Stefania, Lavorgna, Luigi, Barrilà, Caterina, Landi, Doriana, Russo, Cinzia Valeria, Frigeni, Barbara, Ippolito, Domenico, Turano, Gabriella, Carmisciano, Luca, Sormani, Maria Pia, and Signori, Alessio

Abstract

•Patient's age is the most important factor in DMTs choice•Choice of oral drugs vs self-injectables ones is driven by unfavorable prognostic factors•Natalizumab preferred in early stage of severe disease and in younger patients

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results